Samelisant (SUVN-G3031): Positive Results from Phase-2 Proof-of-concept, Double-blind, Placebo-controlled Study in Patients with Narcolepsy and an Update on Further Clinical Development (S6.004)
To evaluate the efficacy and safety of Samelisant for the treatment of excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy.
Authors
- Jyothsna Ravula
- Vijay Benade
- Vinod Goyal (ORCID: https://orcid.org/0000-0002-7325-1914)
- Ramakrishna Nirogi (ORCID: https://orcid.org/0000-0002-2045-0784)
- Venkat Jasti
- Veera Raghava Chowdary Palacharla (ORCID: https://orcid.org/0000-0001-7493-4920)
- Abdul Rasheed Mohammed (ORCID: https://orcid.org/0000-0001-7873-4600)
- Santosh Kumar Pandey
- Anil Shinde
- Pradeep Jayarajan
- Satish Jetta
- Ramkumar Subramanian
- Renny Abraham
Institutions
- Suven Life Sciences (India) (IN)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209070
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00